Ropes & Gray represented Black Diamond Therapeutics in the transaction. Black Diamond Therapeutics (Nasdaq: BDTX) announced a global licensing agreement with French pharmaceutical company Servier for...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Sanofi in the transaction. Sanofi announced an agreement to acquire Dren Bio’s deep B-cell depleter program, DR-0201. The targeted bispecific myeloid cell...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Atavistik Bio on the transaction. Atavistik Bio announced a research collaboration with Pfizer (NYSE: PFE) to accelerate discovery of novel precision allosteric...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Lepu Biopharma in the transaction. Shanghai-based Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) announced an exclusive license agreement with ArriVent BioPharma (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Teva Pharmaceutical Industries in the transaction. Teva Pharmaceutical Industries (NYSE: and TASE: TEVA) announced a license, development and commercialization agreement with Samsung...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Sanofi on the deal. Sanofi announced a strategic equity investment in Torino, Italy-based Resalis Therapeutics (Resalis Therapeutics). The company plans to use...
You must be a Standard 1 Year member to access this content.
Vinge advised Vicore Pharma Holding AB on the deal, and Ropes & Gray advised Sanofi. Vicore Pharma Holding AB (publ) secured a directed share issue, whereby...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Sanofi in the transaction, and Wilson Sonsini Goodrich & Rosati represented Ventyx Biosciences, Inc. Sanofi announced a $27 million strategic investment in...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Sanofi on the transaction, and Goodwin Procter advised Vigil Neuroscience. Sanofi (Nasdaq: SNY) has made a $40 million strategic investment in Vigil...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Ionis Pharmaceuticals in the deal. Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka)...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Nona Biosciences on the deal. Nona Biosciences announced it has entered into a license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for preclinical monoclonal...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Xeris Biopharma Holdings on the transaction. Xeris Biopharma Holdings, Inc. (Nasdaq:XERS) (Xeris), a biopharmaceutical company, announced that it has entered into an exclusive worldwide...
You must be a Standard 1 Year member to access this content.
